NEVRO CORP: management transactions · United States · SEC (Form 4)

About NEVRO CORP

Nevro Corp. (ticker: NVRO) was a U.S. medical device company historically listed on the NYSE in the United States, but it is important to note that it was acquired by Globus Medical and its stock ceased trading on the NYSE on April 3, 2025. For French, Belgian, and Swiss investors, Nevro is still a useful case study in specialized medtech because its business was centered on neuromodulation, specifically spinal cord stimulation (SCS) for chronic pain management. Founded in the mid-2000s, Nevro built its franchise around a differentiated proposition: 10 kHz Therapy, a high-frequency stimulation approach designed to relieve pain without paresthesia. The company is headquartered in Redwood City, California, United States, and developed a reputation as an innovation-led medical device business supported by clinical evidence and a long-term treatment focus. Its flagship offering, the HFX platform, combines the Senza SCS system with physician and patient support services. Operationally, Nevro focused on implantable neuromodulation solutions for chronic pain, with key use cases including back pain and selected neuropathic pain indications. Over time, the company expanded its product stack with HFX iQ and HFX AdaptivAI, adding AI-enabled and cloud-connected features intended to personalize therapy settings and improve the patient journey. That technology-led positioning was central to its competitive profile versus larger neuromodulation peers and broader medtech groups. The company commercialized products in the United States, Europe, and Australia, and described its installed base as serving tens of thousands of patients globally. Its competitive edge came from the combination of proprietary clinical data, a focused pain-management portfolio, and specialization in a niche but structurally attractive market segment. In a crowded neuromodulation landscape, Nevro differentiated itself through evidence-based high-frequency therapy and an expanding digital layer around patient care. The most important recent development was the sale to Globus Medical, announced earlier in 2025 and completed in April 2025, in an all-cash transaction valued at approximately $250 million, or $5.85 per share. Prior to that transaction, Nevro launched HFX AdaptivAI in 2024 and continued to broaden its clinical footprint. For investors, NVRO illustrates how an innovative U.S.-listed health-care company can become part of sector consolidation once scale, reimbursement, and commercialization dynamics converge.